DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Microdosing means doses far below the FDA-approved levels. It is being used off-label — but there are no large trials behind it, and major bodies don’t endorse it. Here is the honest picture.
Bottom line: GLP-1 microdosing (≈0.05–0.25mg semaglutide weekly, vs the standard 0.25–2.4mg) is an off-label practice with no large clinical trials validating it for weight loss. The American Diabetes Association does not endorse it, and no peer-reviewed guideline recommends a protocol. It may reduce side effects and cost, but the weight-loss benefit at these doses is unproven.
The FDA-approved GLP-1 doses were established in large dose-finding trials (STEP for semaglutide, SURMOUNT for tirzepatide) that titrate up to a target maintenance dose. Microdosing deliberately uses a fraction of that — commonly 0.05–0.25mg of semaglutide weekly. Because no branded product is sold at those strengths, microdosing in practice almost always means compounded GLP-1, which is not FDA-approved.
Microdosing is not a proven shortcut and not a proven scam — it is understudied. If a provider offers it, ask: what dose, compounded by which pharmacy (see our pharmacy transparency scorecard), and what outcome are you actually buying given there’s no trial behind it? For an evidence-backed path, the standard-dose, FDA-approved options are reviewed in our full comparison.
Microdosing means taking a GLP-1 medication (usually compounded semaglutide or tirzepatide) at doses far below the FDA-approved range — roughly 0.05–0.25mg weekly for semaglutide, versus the standard 0.25–2.4mg titration. It is an off-label practice, not an approved protocol.
No large-scale clinical trials have validated microdosing for weight loss. The FDA dose-finding trials (STEP, SURMOUNT) studied the standard doses, not microdoses. The American Diabetes Association does not endorse it, and no peer-reviewed guideline recommends a microdosing protocol. Claims are based on clinic experience, not trial data.
The stated goals are fewer gastrointestinal side effects, better tolerability, and lower cost. Some practitioners argue not everyone needs the full dose to see an effect. These are plausible but unproven — there is no trial showing the weight-loss benefit holds at microdoses.
It uses the same molecule, so the known GLP-1 risks apply, and almost all microdosing uses compounded product, which is not FDA-approved and varies in quality. The main issue is the unknown: efficacy and long-term outcomes at these doses have not been studied. Discuss any off-label dosing with a licensed prescriber.
Educational information, not medical advice. Microdosing is off-label; compounded GLP-1 is not FDA-approved. Source on the state of the evidence: Drugs.com clinical Q&A. Do not start or change any medication without a licensed prescriber.